What is a normal fasting LDL‑cholesterol level for adults?

Normal LDL Cholesterol Levels in Adults

For adults with 0-1 risk factors and low cardiovascular risk, a normal LDL cholesterol level is <160 mg/dL, though optimal levels are <100 mg/dL regardless of risk category. 1

Risk-Stratified LDL Targets

The definition of "normal" LDL cholesterol depends entirely on an individual's cardiovascular risk category, as established by the National Cholesterol Education Program ATP III guidelines:

Low-Risk Adults (0-1 Risk Factors)

• Goal LDL-C: <160 mg/dL 1
• These individuals typically have 10-year CHD risk <10% 1
• Diet therapy recommended when LDL ≥160 mg/dL 1
• Drug therapy considered if LDL ≥190 mg/dL after dietary intervention 1

Moderate-Risk Adults (≥2 Risk Factors, 10-Year Risk <10%)

• Goal LDL-C: <130 mg/dL 1
• Drug therapy considered if LDL ≥160 mg/dL on maximal dietary therapy 1

Moderately High-Risk Adults (≥2 Risk Factors, 10-Year Risk 10-20%)

• Goal LDL-C: <130 mg/dL 1
• Therapeutic option: <100 mg/dL based on clinical trial evidence 1
• Drug therapy should be considered if LDL ≥130 mg/dL after dietary therapy 1

High-Risk Adults (CHD or CHD Risk Equivalents)

• Goal LDL-C: <100 mg/dL 1
• Therapeutic option for very high risk: <70 mg/dL 1
• CHD risk equivalents include diabetes, other atherosclerotic disease, or 10-year risk >20% 1
• Drug therapy initiated simultaneously with diet when baseline LDL ≥130 mg/dL 1

Physiologic Context

Research suggests that truly "normal" physiologic LDL levels are actually 50-70 mg/dL, based on levels observed in hunter-gatherers, human neonates, and free-living primates who do not develop atherosclerosis. 2 This challenges conventional definitions and suggests that current guideline targets of 100-115 mg/dL may lead to substantial undertreatment in high-risk individuals. 2

Contemporary Updates

More recent 2018 ACC/AHA guidelines maintain similar risk-stratified approaches but emphasize:

• Very high-risk patients with clinical ASCVD should target LDL <70 mg/dL when on maximally tolerated therapy 1
• Addition of PCSK9 inhibitors or ezetimibe is reasonable when LDL remains ≥70 mg/dL despite maximal statin therapy in very high-risk patients 1

Key Clinical Considerations

Fasting vs. non-fasting measurements: Initial screening can use non-fasting samples, but if triglycerides are ≥400 mg/dL (≥4.5 mmol/L), repeat fasting lipid profile is required for accurate LDL assessment. 1

Measurement accuracy: For LDL <70 mg/dL, direct LDL measurement or modified estimates are more accurate than the Friedewald formula (LDL = Total cholesterol - HDL - triglycerides/5). 1, 3

Diabetes patients: All adults with diabetes are automatically classified as high-risk, with LDL goal <100 mg/dL. 1 The Heart Protection Study supports statin therapy to achieve 30% LDL reduction regardless of baseline LDL in diabetic patients over age 40. 1

Common Pitfalls

• Age and gender: The ATP III guidelines do not adjust LDL targets based on age or gender for screening purposes—total cholesterol >240 mg/dL is considered "high" regardless of demographics. 4
• Undertreatment: Real-world data shows only 33.2% of U.S. adults with high LDL achieve control, particularly among low-income and uninsured populations. 5
• Risk assessment: Framingham risk scoring should be performed in all individuals with ≥2 risk factors to properly stratify 10-year risk and determine appropriate LDL targets. 1